source
- AstraZeneca and CSPC launch joint venture to build biologics plant in ShijiazhuangAstraZeneca and China's CSPC Pharmaceutical have formed a joint venture to construct a biologics manufacturing facility in Shijiazhuang. The agreement follows AstraZeneca's pledge earlier this year…
- Vaderis raises $152 million Series B to launch Phase 3 trial for rare vascular diseaseVaderis Therapeutics announced it has closed an oversubscribed $152 million Series B round to fund its AKT inhibitor program. The capital will support a newly launched Phase 3 study of the oral dr…